Indian Researchers Develop RK-251 as Smart Cancer Drug to Target ROS
· Technology · Indian Express, Hindustan Times
Researchers in India have developed an experimental cancer drug named RK-251 designed to activate preferentially inside cancer cells by exploiting elevated levels of reactive oxygen species. The collaborative research was led by Dr Asis Bala from the Institute of Advanced Study in Science and Technology and Dr K P Bhabak from the Indian Institute of Technology-Guwahati. Preclinical studies demonstrated strong activity against aggressive triple-negative breast cancer cells while sparing healthy tissue. Testing on zebrafish embryos showed no obvious signs of toxicity alongside desired fluorescence, though further validation and clinical trials in patients are required. The findings were published in the ACS Journal of Medicinal Chemistry.
Why it matters
This breakthrough offers a potential alternative to traditional chemotherapy by targeting cancer cells selectively, minimizing adverse side effects on healthy organs.
Read the original report — Indian Express
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.